Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,447.51
(
-0.72%
)
US TECH 100
28,560.00
(
-0.80%
)
Dow Jones
49,632.49
(
-0.86%
)
Brent Oil
106.70
(
2.42%
)
Bitcoin
79,462.16
(
-1.97%
)
News Focus
News Focus
Post# of 1367
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122986
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 928

Saturday, 11/15/2008 2:56:53 AM

Saturday, November 15, 2008 2:56:53 AM

Post# of 1367
genisi: According to Kamada’s recent Oppenheimer webcast, IV AAT has a bioavailability to the lung tissue of 2% and inhaled AAT has a bioavailability of almost 100%. However, the amount of AAT per IV dose is only four times greater than the amount of AAT per inhaled dose.

If the 2% figure given on the webcast is correct, why isn’t the amount of AAT per IV dose about fifty times greater than the amount per inhaled dose? T.i.a.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today